Amy Wise,Jingyao Li,Mai Yamakawa,Joseph Loureiro,Brant Peterson,Kathleen Worringer,Rajeev Sivasankaran,Jose-Alberto Palma,Laura Mitic,Hilary W Heuer,Argentina Lario-Lago,Adam M Staffaroni,Annie Clark,Jack Taylor,Peter A Ljubenkov,Lawren Vandevrede,Lea T Grinberg,Salvatore Spina,William W Seeley,Bruce L Miller,Bradley F Boeve,Bradford C Dickerson,Murray Grossman,Irene Litvan,Alexander Pantelyat,Maria Carmela Tartaglia,Zihan Zhang,Anne-Marie A Wills,Jessica Rexach,Julio C Rojas,Adam L Boxer,as the 4-Repeat Tauopathy Neuroimaging Initiative

Abstract:Background and objectives: Identification of fluid biomarkers for progressive supranuclear palsy (PSP) is critical to enhance therapeutic development. We implemented unbiased DNA aptamer (SOMAmer) proteomics to identify novel CSF PSP biomarkers. Methods: This is a cross-sectional study in original (18 clinically diagnosed PSP-Richardson syndrome [PSP-RS], 28 cognitively healthy controls]), validation (23 PSP-RS, 26 healthy controls), and neuropathology-confirmed (21 PSP, 52 non-PSP frontotemporal lobar degeneration) cohorts. Participants were recruited through the University of California, San Francisco, and the 4-Repeat Neuroimaging Initiative. The original and neuropathology cohorts were analyzed with the SomaScan platform version 3.0 (5026-plex) and the validation cohort with version 4.1 (7595-plex). Clinical severity was measured with the PSP Rating Scale (PSPRS). CSF proteomic data were analyzed to identify differentially expressed targets, implicated biological pathways using enrichment and weighted consensus gene coexpression analyses, diagnostic value of top targets with receiver-operating characteristic curves, and associations with disease severity with linear regressions. Results: A total of 136 participants were included (median age 70.6 ± 8 years, 68 [50%] women). One hundred fifty-five of 5,026 (3.1%), 959 of 7,595 (12.6%), and 321 of 5,026 (6.3%) SOMAmers were differentially expressed in PSP compared with controls in original, validation, and neuropathology-confirmed cohorts, with most of the SOMAmers showing reduced signal (83.1%, 95.1%, and 73.2%, respectively). Three coexpression modules were associated with PSP across cohorts: (1) synaptic function/JAK-STAT (β = -0.044, corrected p = 0.002), (2) vesicle cytoskeletal trafficking (β = 0.039, p = 0.007), and (3) cytokine-cytokine receptor interaction (β = -0.032, p = 0.035) pathways. Axon guidance was the top dysregulated pathway in PSP in original (strength = 1.71, p < 0.001), validation (strength = 0.84, p < 0.001), and neuropathology-confirmed (strength = 0.78, p < 0.001) cohorts. A panel of axon guidance pathway proteins discriminated between PSP and controls in original (area under the curve [AUC] = 0.924), validation (AUC = 0.815), and neuropathology-confirmed (AUC = 0.932) cohorts. Two inflammatory proteins, galectin-10 and cytotoxic T lymphocyte-associated protein-4, correlated with PSPRS scores across cohorts. Discussion: Axon guidance pathway proteins and several other molecular pathways are downregulated in PSP, compared with controls. Proteins in these pathways may be useful targets for biomarker or therapeutic development.

A human Tau expressing zebrafish model of progressive supranuclear palsy identifies Brd4 as a regulator of microglial synaptic elimination

Cross species systems biology discovers glial DDR2, STOM , and KANK2 as therapeutic targets in progressive supranuclear palsy

Tau P301S Transgenic Mice Develop Gait and Eye Movement Impairments That Mimic Progressive Supranuclear Palsy

Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo

Mitochondrial Complex 1 Inhibition Increases 4-Repeat Isoform Tau by Srsf2 Upregulation

Fully Human Bifunctional Intrabodies Achieve Graded Reduction of Intracellular Tau and Rescue Survival of MAPT Mutation iPSC-derived Neurons

MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy

Post mortem validation and mechanistic study of UCB‐J in progressive supranuclear palsy patients' brains

PERK activation mitigates tau pathology in vitro and in vivo

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis

Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy

Human iPSC 4R tauopathy model uncovers modifiers of tau propagation

CSF Proteomics in Patients With Progressive Supranuclear Palsy

Evidence for trans-synaptic propagation of oligomeric tau in Progressive Supranuclear Palsy

P2‐025: Genetic and Epigenetic Influences on Brain Gene Expression in Psp

18F-APN-1607 Tau PET in Progressive Supranuclear Palsy-Like Symptoms Caused by TBK1 Mutations

Single-cell transcriptomic and neuropathologic analysis reveals dysregulation of the integrated stress response in progressive supranuclear palsy

5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy

Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes

Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a knock-in tauopathy model

Dominance of Tau Burden in Cortical Over Subcortical Regions Mediates Glymphatic Activity and Clinical Severity in PSP